Bio-Path Holdings, Inc.

Equities

BPTH

US09057N4097

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 15/06/2024 am IST			5-day change	1st Jan Change
2.16 ^USD	+8.00%		-12.90%	-76.67%

14/06	Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	CI
05/06	Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	CI

Bio-Path Holdings, Inc. Appoints Michael J. Garrison as Director

October 03, 2012 at 10:36 pm IST

On October 1, 2012, the board of directors of Bio-Path Holdings, Inc. increased the size of the Board from three to four members and elected Michael J. Garrison as a director of the company to fill the vacancy created by such increase. In connection with Mr. Garrison's election to the Board.

Latest news about Bio-Path Holdings, Inc.

Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At European Hematology Association Congress	14/06	CI
Bio-Path Holdings, Inc. announced that it has received $4.000001 million in funding	05/06	CI
Bio-Path Holdings, Inc. announced that it expects to receive $4.000001 million in funding	04/06	CI
Sector Update: Health Care Stocks Gain Late Afternoon	04/06	MT
Top Midday Gainers	03/06	MT
Wall Street Set to Open Slightly Higher Monday as Investors Await Key Manufacturing Data for May	03/06	MT
Investors Await Key Manufacturing Data as US Futures Nudge Higher in Monday's Premarket Session	03/06	MT
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia At American Society of Clinical Oncology Annual Meeting	03/06	CI
Transcript : Bio-Path Holdings, Inc., Q1 2024 Earnings Call, May 15, 2024	15/05
Bio-Path Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Bio-Path Closes $1.2 Million Share Offering	19/04	MT
Bio-Path Holdings, Inc. Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients	18/04	CI
Bio-Path Holdings, Inc. Expands Global Patent Portfolio	15/04	CI
North American Morning Briefing : Investors on Edge as High-Stakes Jobs Report Awaited	05/04	DJ
Transcript : Bio-Path Holdings, Inc., Q4 2023 Earnings Call, Mar 08, 2024	08/03
North American Morning Briefing : Stock Futures -2-	08/03	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08/03	CI
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients	10/01	CI
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1B Clinical Trial of Bp1002 in Refractory/Relapsed Acute Myeloid Leukemia	14/12	CI
Transcript : Bio-Path Holdings, Inc., Q3 2023 Earnings Call, Nov 15, 2023	15/11
North American Morning Briefing : Stocks Seen -2-	15/11	DJ
Bio-Path Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Certain Warrants of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	01/11	CI
Certain Options of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	01/11	CI
Certain Common Stock of Bio-Path Holdings, Inc. are subject to a Lock-Up Agreement Ending on 1-NOV-2023.	01/11	CI

Chart Bio-Path Holdings, Inc.

Duration

Period

More charts

Company Profile

Bio-Path Holdings, Inc. is a biotechnology company. The Company is engaged in developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the DNA from destruction by the bodyâs enzymes when circulating in vivo, incorporated inside of a lipid bilayer having neutral charge. Its lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase II study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase I/Ib study for solid tumors. The Companyâs second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. BP1003 is its third liposome delivered antisense drug candidate.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.16 USD

Average target price

20 USD

Spread / Average Target

+825.93%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIO-PATH HOLDINGS, INC.	-76.67%	44.93L
MODERNA, INC.	+40.80%	5.37TCr
LONZA GROUP AG	+35.79%	3.89TCr
IQVIA HOLDINGS INC.	-8.05%	3.88TCr
CELLTRION, INC.	-8.98%	2.73TCr
ICON PUBLIC LIMITED COMPANY	+10.69%	2.59TCr
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	2.03TCr
UNITED THERAPEUTICS CORPORATION	+31.00%	1.28TCr
MEDPACE HOLDINGS, INC.	+28.51%	1.22TCr
BIO-TECHNE CORPORATION	-1.67%	1.2TCr

Other Biotechnology & Medical Research